Dolasynthen, Publications, XMT-1660

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer

Dolasynthen, Publications, XMT-1660

XMT‑1660: A Phase 1b Trial of a B7‑H4–Targeting Antibody‑Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers

Dolasynthen, Publications, XMT-1660

XMT-1660: A Phase 1b Trial of a B7-H4–targeting Antibody-Drug Conjugate (ADC) in Endometrial, Ovarian, and Breast Cancers

Dolasynthen, Publications, XMT-1660

Anti-tumor Effect of XMT-1660, a B7-H4 Targeting Antibody Drug Conjugate, in an Unselected Panel of Patient Derived Xenograft Models of Breast Cancer

April, 2022

Dolasynthen, Platform, Publications, XMT-1660

XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer

April, 2021